JP2020503362A5 - - Google Patents

Download PDF

Info

Publication number
JP2020503362A5
JP2020503362A5 JP2019536919A JP2019536919A JP2020503362A5 JP 2020503362 A5 JP2020503362 A5 JP 2020503362A5 JP 2019536919 A JP2019536919 A JP 2019536919A JP 2019536919 A JP2019536919 A JP 2019536919A JP 2020503362 A5 JP2020503362 A5 JP 2020503362A5
Authority
JP
Japan
Prior art keywords
antibody
seq
cdr
fibrosis
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019536919A
Other languages
English (en)
Japanese (ja)
Other versions
JP7157744B2 (ja
JP2020503362A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/012601 external-priority patent/WO2018129329A1/en
Publication of JP2020503362A publication Critical patent/JP2020503362A/ja
Publication of JP2020503362A5 publication Critical patent/JP2020503362A5/ja
Priority to JP2022162088A priority Critical patent/JP2022188226A/ja
Application granted granted Critical
Publication of JP7157744B2 publication Critical patent/JP7157744B2/ja
Priority to JP2024172672A priority patent/JP2025000891A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019536919A 2017-01-06 2018-01-05 アイソフォーム特異的な、コンテクスト寛容TGFβ1阻害剤およびその使用 Active JP7157744B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022162088A JP2022188226A (ja) 2017-01-06 2022-10-07 アイソフォーム特異的な、コンテクスト寛容TGFβ1阻害剤およびその使用
JP2024172672A JP2025000891A (ja) 2017-01-06 2024-10-01 アイソフォーム特異的な、コンテクスト寛容TGFβ1阻害剤およびその使用

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201762443615P 2017-01-06 2017-01-06
US62/443,615 2017-01-06
US201762452866P 2017-01-31 2017-01-31
US62/452,866 2017-01-31
US201762514417P 2017-06-02 2017-06-02
US62/514,417 2017-06-02
US201762529616P 2017-07-07 2017-07-07
US62/529,616 2017-07-07
US201762549767P 2017-08-24 2017-08-24
US62/549,767 2017-08-24
US201762558311P 2017-09-13 2017-09-13
US62/558,311 2017-09-13
US201762585227P 2017-11-13 2017-11-13
US62/585,227 2017-11-13
US201762587964P 2017-11-17 2017-11-17
US62/587,964 2017-11-17
US201762588626P 2017-11-20 2017-11-20
US62/588,626 2017-11-20
PCT/US2018/012601 WO2018129329A1 (en) 2017-01-06 2018-01-05 ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022162088A Division JP2022188226A (ja) 2017-01-06 2022-10-07 アイソフォーム特異的な、コンテクスト寛容TGFβ1阻害剤およびその使用

Publications (3)

Publication Number Publication Date
JP2020503362A JP2020503362A (ja) 2020-01-30
JP2020503362A5 true JP2020503362A5 (cg-RX-API-DMAC7.html) 2021-02-12
JP7157744B2 JP7157744B2 (ja) 2022-10-20

Family

ID=61198888

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019536919A Active JP7157744B2 (ja) 2017-01-06 2018-01-05 アイソフォーム特異的な、コンテクスト寛容TGFβ1阻害剤およびその使用
JP2022162088A Pending JP2022188226A (ja) 2017-01-06 2022-10-07 アイソフォーム特異的な、コンテクスト寛容TGFβ1阻害剤およびその使用
JP2024172672A Pending JP2025000891A (ja) 2017-01-06 2024-10-01 アイソフォーム特異的な、コンテクスト寛容TGFβ1阻害剤およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022162088A Pending JP2022188226A (ja) 2017-01-06 2022-10-07 アイソフォーム特異的な、コンテクスト寛容TGFβ1阻害剤およびその使用
JP2024172672A Pending JP2025000891A (ja) 2017-01-06 2024-10-01 アイソフォーム特異的な、コンテクスト寛容TGFβ1阻害剤およびその使用

Country Status (17)

Country Link
US (3) US20180207267A1 (cg-RX-API-DMAC7.html)
EP (1) EP3551658A1 (cg-RX-API-DMAC7.html)
JP (3) JP7157744B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240137126A (cg-RX-API-DMAC7.html)
CN (2) CN110382530A (cg-RX-API-DMAC7.html)
AU (2) AU2018205231A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019013908A2 (cg-RX-API-DMAC7.html)
CA (1) CA3049005A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019001874A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019007298A2 (cg-RX-API-DMAC7.html)
CR (1) CR20190350A (cg-RX-API-DMAC7.html)
DO (1) DOP2019000180A (cg-RX-API-DMAC7.html)
IL (2) IL267790A (cg-RX-API-DMAC7.html)
MX (1) MX429001B (cg-RX-API-DMAC7.html)
PE (1) PE20191661A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019501575A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018129329A1 (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2951648T3 (es) 2016-03-11 2023-10-24 Scholar Rock Inc Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas
CN110382530A (zh) * 2017-01-06 2019-10-25 供石公司 亚型特异性、背景许可性TGFβ1抑制剂及其用途
EP3658583A1 (en) * 2017-07-28 2020-06-03 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
KR102891320B1 (ko) 2018-07-11 2025-11-28 스칼러 락, 인크. 고친화도, 이소형-선택적 TGFβ1 억제제 및 그의 용도
PT3677278T (pt) 2018-07-11 2022-02-03 Scholar Rock Inc Inibidores seletivos da isoforma tgfbeta1 e sua utilização
EP3820896A1 (en) 2018-07-11 2021-05-19 Scholar Rock, Inc. TGFbeta1 INHIBITORS AND USE THEREOF
EP3863722A2 (en) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap antibody variants and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
SG11202108099WA (en) 2019-01-30 2021-08-30 Scholar Rock Inc LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF
SG11202110338XA (en) 2019-03-27 2021-10-28 Singapore Health Serv Pte Ltd Biomarker with therapeutic implications for peritoneal carcinomatosis
WO2020206055A1 (en) * 2019-04-02 2020-10-08 Yale University Methods of treatment of diseases and disorders associated with increased tet level, increased h19 level, increased level of tgf signaling, or any combination thereof
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
CN120022360A (zh) 2019-08-28 2025-05-23 中外制药株式会社 跨物种抗潜伏TGF-β1抗体和使用方法
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
CA3166328A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
CA3167427A1 (en) * 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgfb inhibitors and use thereof
WO2021195418A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
US20230122364A1 (en) * 2020-03-27 2023-04-20 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
BR112022021780A2 (pt) 2020-04-27 2023-03-07 Twist Bioscience Corp Bibliotecas de ácido nucléico variantes para coronavírus
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
CN116723861A (zh) * 2020-12-02 2023-09-08 上海复宏汉霖生物技术股份有限公司 抗GARP/TGFβ抗体及使用方法
CN114957476A (zh) * 2021-02-23 2022-08-30 复旦大学 一种半胱氨酸工程化的结合人5t4的全人源纳米抗体
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
US20250282857A1 (en) * 2021-03-26 2025-09-11 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
AU2022273631B2 (en) 2021-05-11 2025-04-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
EP4348260A2 (en) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof
JP7892764B2 (ja) * 2021-08-11 2026-07-21 イミュニティーバイオ インコーポレイテッド 多重鎖キメラポリペプチド及び肝疾患の治療におけるその使用
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
CN119255993A (zh) 2022-03-22 2025-01-03 奥托泰利克生物公司 噻唑衍生物化合物及其用途
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
EP4676954A1 (en) 2023-03-07 2026-01-14 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
CN117721079B (zh) * 2024-01-26 2025-03-11 广东壹加再生医学研究院有限公司 一种促进nk细胞抗肿瘤活性的培养基及培养方法
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
JPH11507843A (ja) 1996-03-28 1999-07-13 ザ・ジョンズ・ホプキンス・ユニバーシティー タンパク質の可溶性二価および多価ヘテロ二量体類縁体
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
PE20020132A1 (es) 2000-06-29 2002-03-04 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos
GB0230202D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Ligand
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CA2597098C (en) 2005-02-08 2016-08-02 Steven R. Ledbetter Antibodies to tgfbeta
BRPI0809042B1 (pt) * 2007-03-22 2021-08-31 Biogen Ma Inc. Proteína de ligação a cd154 isolada, seu uso, e composição
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
JO3096B1 (ar) * 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
WO2011102483A1 (ja) * 2010-02-19 2011-08-25 独立行政法人理化学研究所 ヒトTGF-βのLAPに結合する抗体
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
RU2563830C2 (ru) * 2011-02-08 2015-09-20 Эббви Инк. Лечение остеоартрита и боли
EP2714735B1 (en) * 2011-06-03 2021-07-21 XOMA Technology Ltd. Antibodies specific for tgf-beta
MX2014005570A (es) * 2011-11-08 2014-05-30 Pfizer El uso de anticuerpos anti factor estimulante de la colonia de macrofagos para tratar trastornos inflamatorios.
SMT201800092T1 (it) 2011-11-14 2018-03-08 Regeneron Pharma Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a
WO2013134365A1 (en) * 2012-03-08 2013-09-12 Ludwig Institute For Cancer Research Ltd TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
HRP20201914T1 (hr) * 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
WO2015171691A2 (en) * 2014-05-06 2015-11-12 Scholar Rock, Inc. Compositions and methods for growth factor modulation
SG11201705721WA (en) * 2015-01-14 2017-08-30 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
ES2951648T3 (es) 2016-03-11 2023-10-24 Scholar Rock Inc Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas
CN110382530A (zh) * 2017-01-06 2019-10-25 供石公司 亚型特异性、背景许可性TGFβ1抑制剂及其用途

Similar Documents

Publication Publication Date Title
JP7835788B2 (ja) シトルリン化されたヒストン2a及び/又は4に結合する抗体
KR101676269B1 (ko) 인터루킨-13 결합 단백질
JP6100463B2 (ja) TNFαを阻害する安定かつ可溶性の抗体
JP5164829B2 (ja) 新規な抗plgf抗体
JP2011504501A5 (cg-RX-API-DMAC7.html)
JP2018108081A5 (cg-RX-API-DMAC7.html)
CN106103479B (zh) 识别其它ccr3-结合趋化因子的抗嗜酸粒细胞趋化因子-2抗体
JP2019505527A5 (cg-RX-API-DMAC7.html)
JP2016519650A5 (cg-RX-API-DMAC7.html)
JP2008518936A5 (cg-RX-API-DMAC7.html)
JP2010527356A5 (cg-RX-API-DMAC7.html)
JP2017537084A5 (cg-RX-API-DMAC7.html)
JP2018093875A5 (cg-RX-API-DMAC7.html)
JP2017113019A5 (cg-RX-API-DMAC7.html)
JP2017535285A5 (cg-RX-API-DMAC7.html)
CN103974976A (zh) 用于治疗炎性病症的il17c拮抗剂
JP2011518857A5 (cg-RX-API-DMAC7.html)
JP2015518857A5 (cg-RX-API-DMAC7.html)
JPWO2020059847A5 (cg-RX-API-DMAC7.html)
CN116059350A (zh) 使用抗-il-17a/f抗体的治疗方法
RU2008140947A (ru) Антитела к egfl7 и способы их применения
JP2022548646A5 (cg-RX-API-DMAC7.html)
JP2015518368A (ja) IL‐1β中和ヒトモノクローナル抗体
JP2016006052A5 (cg-RX-API-DMAC7.html)
JP2022542805A (ja) メタロチオネイン抗体およびそれらの使用